secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nabriva Therapeutics plc (—)
CIK:        0001641640
Form:       8-K
Filed at:   2023-07-07T23:59:59+00:00
Accession:  0001104659-23-079156
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nabriva Therapeutics CFO and interim CEO depart; restructuring consultants take over
--------------------------------------------------------------------------------

- CFO Daniel Dolan separated June 30, 2023; interim CEO/GC J. Christopher Naftzger separated July 7, 2023.
- Both executives receive 12 months base salary, COBRA premium payments, 100% target bonus, accelerated equity vesting.
- H. Michael Hogan appointed CEO and Dave Maggio appointed CFO effective July 7 and June 30 respectively, via Armanino LLP consulting agreement.
- Hogan and Maggio are partners/directors at Armanino, a restructuring firm; consulting fees $425-$650/hr and $375-$495/hr respectively.
- Appointments part of Cash Preservation Plan to wind down operations; consulting agreements expire Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923079156/0001104659-23-079156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641640/000110465923079156/tm2320799d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer